- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01682018
The Value of Bronchoscopic Lung Volume Reduction by Endobronchial Valves in Patients With Single Lung Transplantation and Overinflation of the Native Lung
Clinical Trial to Evaluate the Value of Bronchoscopic Lung Volume Reduction by Endobronchial Valves in Patients With Single Lung Transplantation and Overinflation of the Native Lung
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Emphysema is a progressive pulmonary disease characterized by abnormal and permanent enlargement of air spaces distal to terminal bronchioles accompanied by the destruction of pulmonary parenchyma. Treatment includes inhaled bronchodilator therapy, rehabilitation and/or oxygen treatment. In addition to the above, patients with severe emphysema may benefit from surgical lung volume reduction and/or lung transplantation. The rationale for lung volume reduction surgery is that reducing lung size would restore elastic recoil of the lung and improve chest wall and diaphragm mechanics. It has previously been shown that particularly patients with heterogeneous emphysema seem to benefit most from surgical lung volume reduction.
Bronchoscopic lung volume reduction (BLVR) has recently been introduced as a less invasive potential alternative to surgical lung volume reduction. BLVR attempts to achieve the effects of surgery, by placing bronchial prostheses using a fibreoptic bronchoscope to selectively occlude the airways supplying the most affected hyperinflated regions of the emphysematous lung, while permitting exhaled gas to escape. This attempts to achieve segmental or lobar volume reduction, simulating the effects of surgical LVR.
The purpose of the study is to investigate if bronchoscopic lung volume reduction by valves (Zephyr) would reduce native lung overinflation in patients that underwent single lung transplantation due to emphysema, and improve their well being and pulmonary function tests
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Petah Tikva, Israel, 92100
- Rabin Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Single lung transplantation due to emphysema at least six months following transplantation that developed native lung overinflation
- Age from 40 to 75 years
- BMI < 32 kg/m2
- FEV1 < 40% of predicted value, FEV1/FVC < 70%
- TLC > 120% predicted, RV > 150% predicted.
- Stable with < 20 mg prednisone (or equivalent) qd
- PaCO2 < 50mm Hg
- PaO2 > 45 mm Hg on room air
- 6-min walk of > 50m (without rehabilitation) or > 100m (with rehabilitation)
- Nonsmoking for 4 months prior to initial interview and throughout screening
- The patient agrees to all protocol required follow-up intervals.
- The patient has no child bearing potential
- The patient is willing and able to complete protocol required baseline assessments and procedures Exclusion criteria
- Prior endobronchial treatment for emphysema
- Pleural or interstitial disease that precludes surgery.
- Prior lung transplant, LVRS, median sternotomy, bullectomy or lobectomy.
- Clinically significant bronchiectasis
- Pulmonary nodule requiring surgery
- History of recurrent respiratory infections (> 3 hospitalization in the last year)
- Clinically significant (> 4 Tablespoons per day) sputum production
- Fever, elevated white cell count, or other evidence of active infection
- Dysrhythmia that might pose a risk during exercise or training
- Congestive heart failure within 6 mo and LVEF < 45%
- Evidence or history of Cor Pulmonale
- Resting bradycardia (< 50 beats/min), frequent multifocal PVCs, complex ventricular arrhythmia, sustained SVT
- History of exercise-related syncope
- MI within 6 mo and LVEF < 45%
- Evidence of systemic disease or neoplasia expected to compromise survival during 5-yr period
- Any disease or condition that interferes with completion of initial or follow-up assessments
- Patient is currently enrolled in another clinical trial
- Patient is unable to complete 3 minutes of unloaded peddling on cycle ergometer
- Alpha-1-Antitrypsin Deficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: intervention group
Patients that underwent dingle lung transplantation due to emphysema and developed native lung overinflation as demonstrated by chest CT and decline in pulmonary lung function tests (FEV1 ) shall undergo valves placement to the native lung
|
lung volume reduction using the Zephyr device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
•Mean % change in lung function (FEV1)
Time Frame: 90 days
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change in six minutes walk distance
Time Frame: 90 days
|
90 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RMC126908
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Native Lung Overinflation in Patients That Underwent Single Lung Transplantation Due to Emphysema
-
Hyundai PharmCompletedEvaluate the Efficacy and Safety of Levotuss CR Tab. in Comparison With Levotuss Syrup in Patients With Cough Due to Acute or Chronic BronchitisKorea, Republic of
-
Bulgarian Cardiac InstituteCompletedto Find a Clinical or Laboratory Parameter, That Would Help in Distinguishing Between COVID-19 Patients With MI and IRA and Those, Who Have no IRABulgaria
Clinical Trials on lung volume reduction using the Zephyr device
-
Pulmonx CorporationActive, not recruitingEmphysema | COPD | Severe EmphysemaUnited Kingdom, France, Netherlands, Germany, Australia, Italy, Switzerland
-
Pulmonx CorporationCompletedCOPD | Heterogeneous EmphysemaNetherlands, Sweden, United Kingdom, Germany, France, Belgium
-
Pulmonx CorporationActive, not recruiting
-
Boston Scientific CorporationPneumRx, Inc.CompletedEmphysemaNetherlands, Germany, France
-
China-Japan Friendship HospitalNot yet recruitingChronic Obstructive Pulmonary Disease | EmphysemaChina
-
Universität Duisburg-EssenRecruiting
-
Boston Scientific CorporationPneumRx, Inc.CompletedEmphysemaGermany, Netherlands
-
Boston Scientific CorporationPneumRx, Inc.Completed
-
University Medical Center GroningenCompletedEmphysema | COPDNetherlands
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedLung Diseases | Lung Diseases, Obstructive | Chronic Obstructive Pulmonary Disease | Emphysema